NanoSphere pioneering innovative cannabinoid delivery technology


NanoSphere Health Sciences Inc. (CSE: NSHS) has developed an innovative delivery technology that increases up to six-fold the bioavailability of cannabinoids, marking a significant step forward in the medical cannabis sector.

Inconsistent delivery of cannabinoids has plagued the industry for decades and may be one reason why the medicine became mired on a prohibition, as pharmaceutical companies could not commercialize single drug products to fit the emerging pattern of drug commercialization at the turn of the nineteenth century.

The lack of sturdy delivery mechanisms is a significant impediment in the use of cannabinoids. In a 2009 study, researchers found that the bioavailability varied from 2-56% for inhaled cannabis smoke, and to 4-20% for oral consumption. They found that the absorption of inhaled cannabinoids varies widely between individuals, whereas cannabinoids administered orally degrade in the stomach as well as during first-pass metabolism in the liver.

Smoking is not appealing or possible for health, lifestyle, or regulated reasons such as, for example, hospitals or nursing homes.

Topical delivery can be problematic because current topical cannabinoid preparations suffer from many formulation issues such as weak or inert creams and poor absorption, and they are often not very consumer friendly (e.g. greasy or oily).

Transdermal cannabinoid delivery provides an attractive alternative route of administration since it reduces the negative side effects associated with inhaled dosing and bypasses first-pass metabolism in the liver.

The NanoSphere Delivery System™ transports active ingredients directly into the bloodstream and cells using patent-pending natural lipid nanoparticle structures through a transdermal application.

With an existing licensing agreement, the company is also well on its way to commercialization after spending more than a decade fine-tuning its technology – and developing products that have applications across an array of industries. Investors may want to take a closer look at the stock as a potential opportunity in the space.

The products immediately penetrate the skin to deliver direct-focused relief from pain, inflammation and anxiety and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors through the body for systemic healing and is recommended for:

  • For pain, muscle aches, tension and soreness; apply to the affected area of the body.
  • For quick relief from headaches, apply to the temples and forehead.
  • To comfort menstrual cramps and abdominal pain; apply to the abdominal area of discomfort.
  • To ease joint pain or stiffness, apply to skin around painful joints and vertebraes.
  • To soothe anxiety, apply to pulse points such as the inner wrists.

NanoSphere’s technology also applies to other lipophilic (fat-soluble) medicines. Approximately 40 percent of lipophilic medications fail in clinical trials because of their lack of water solubility and formulation instability. The insolubility, degeneration by digestive enzymes, pre-systemic metabolism, poor intestinal absorption, and removal from the liver prevents them from reaching threshold levels for activity.

The U.S. cannabis industry is projected to exceed $50 billion in size over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis in California and other states. While there are many opportunities for investors in the space, since they generate high-margin licensing revenue and don’t touch the plant, biotech firms developing innovative delivery mechanisms offer investors a compelling opportunity.

On January 23, the company announced that it signed an agreement to license its technology in the State of California to an Oakland-based licensee, which is a private-label manufacturer of pharmaceutical goods for more than 35 leading brands in the legal cannabis space and the agreement provides the manufacturer with a non-exclusive license to the patent-pending NanoSphere Delivery System™ and its branded Evolve NanoSerum line.


Samuel TheilComment